Abstract 106P
Background
Stage I-III squamous cell cancers (SCC) of the anal canal are treated with definitive concurrent chemoradiotherapy. Capecitabine (Cape) and mitomycin-C (MMC) chemotherapy is an approved concurrent regimen, but with limited evidence.
Methods
A retrospective analysis of stage I-III SCC patients treated at Tata Memorial hospital with concurrent Cape-MMC (Capecitabine 1250mg/m2 PO continuous with IV Mitomycin C 12mg/m2 on D1) based chemoradiotherapy from March 2014 to March 2020 was conducted. Patients were staged as per American Joint Committee on Cancer, seventh edition. The primary outcome of the study was recurrence-free survival (RFS). Overall survival (OS) and RFS were calculated by Kaplan-Meier estimates.
Results
Two hundred and twenty-six patients were included in the study, with the median age being 58 (range: 22-81) years. Stage I, stage II, and stage III cancers were seen in 1(0.4%), 62 (27.4%), and 163 (72.1%) patients, respectively. Patients received a median 45 Gy (range; 20-63) in 25 fractions as definitive radiotherapy with concurrent Cape-MMC. Response evaluation at 6 months was available in 190 patients, with 51 patients (27%) having local residual or progressive disease. Nine patients (4%) underwent salvage surgery. At a median follow up of 28 months, 38 recurrences had occurred, with 13 patients having only local recurrence while 25 patients had distant metastasis, with or without local recurrences. The median 2-year RFS was 82%, while median 2 years OS was 85%. Patients with stage III disease had inferior RFS as compared to patients with stage I/II disease (2 year RFS: 78% vs. 90%; p=0.042) Common grade 3 and grade 4 toxicities were local skin reactions in 44 (21.4%), neutropenia and thrombocytopenia in 9 (4.4%) patients, respectively.
Conclusions
The current study using chemoradiation with Cape-MMC is a large study in predominantly stage III anal canal cancers and shows excellent loco-regional control rates and tolerance in comparison to the traditional 5 fluorouracil-based regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session